Alpha-GPC (Alpha-Glycerylphosphorylcholine)
Updated September 29, 2026 · By Sophie Callahan
The Short Answer
Alpha-GPC (alpha-glycerylphosphorylcholine) is a choline compound that serves as a precursor to acetylcholine, a neurotransmitter critical for memory, attention, and neural signaling. It is one of the most bioavailable forms of choline, crossing the blood-brain barrier more efficiently than choline bitartrate or choline citrate. Clinical studies for cognitive endpoints typically use 400–1,200 mg/day. Alpha-GPC is included in some hearing support formulas based on acetylcholine's role in auditory processing, though direct tinnitus evidence is lacking.
What is Alpha-GPC (Alpha-Glycerylphosphorylcholine)?
Alpha-GPC (alpha-glycerylphosphorylcholine, also known as choline alfoscerate) is a phospholipid-based choline compound found naturally in the brain and in small amounts in foods like eggs, organ meats, and soy. It is one of the most bioavailable supplemental forms of choline — upon ingestion, it is metabolized to release choline and glycerophosphate, both of which contribute to cell membrane integrity and neurotransmitter production. Unlike choline bitartrate, Alpha-GPC crosses the blood-brain barrier efficiently, which is why it has become the preferred choline source in nootropic and cognitive health formulas.
How it works
Alpha-GPC's primary mechanism is supporting acetylcholine synthesis. Acetylcholine is a key neurotransmitter involved in memory formation, attention, learning, and muscle contraction. By providing a highly bioavailable choline source, Alpha-GPC helps maintain acetylcholine levels — particularly relevant during aging, when choline metabolism becomes less efficient. Beyond acetylcholine, Alpha-GPC supports phosphatidylcholine synthesis, contributing to neuronal membrane integrity and potentially supporting neuroplasticity. In the context of auditory health, acetylcholine plays a role in the efferent auditory system — the feedback pathway from the brain to the cochlea that modulates how the inner ear processes sound. This cholinergic pathway is one reason Alpha-GPC appears in some hearing support formulas.
What the evidence says
Alpha-GPC has been studied primarily for cognitive outcomes, with most clinical evidence coming from trials involving age-related cognitive decline and dementia. The evidence for auditory or tinnitus-specific applications is indirect, based on acetylcholine's role in auditory processing rather than direct clinical trials.
- Alpha-GPC improved cognitive function in patients with mild to moderate dementia across multiple clinical trials. — A systematic review evaluating choline alfoscerate (Alpha-GPC) across 13 published clinical trials found consistent cognitive benefits in patients with degenerative and vascular dementia. (Systematic review of 13 clinical trials)
- Alpha-GPC (1,200 mg/day) produced meaningful cognitive improvement in Alzheimer's patients over 180 days. — A multicenter, double-blind, randomized, placebo-controlled trial of Alpha-GPC at 1,200 mg/day in 261 patients with mild to moderate Alzheimer's disease, showing significant improvements in cognitive assessments after 90 and 180 days. (2003 RCT, 261 patients)
Effective dosage
Clinical studies for cognitive endpoints typically use 400–1,200 mg/day of Alpha-GPC, with 1,200 mg/day (divided into three 400 mg doses) being the most common protocol in dementia trials. Athletic performance studies have used single doses of 600 mg. The minimum threshold for measurable cognitive effects in published trials appears to be around 400 mg/day.
For supplements using proprietary blends or undisclosed doses, the concern is whether Alpha-GPC is present in a meaningful amount. In a multi-ingredient formula where total active content is limited (especially in spray formats), achieving even the minimum studied dose of 400 mg is challenging when shared across several compounds.
Safety and interactions
Alpha-GPC is generally well tolerated at doses up to 1,200 mg/day in clinical trials. Reported side effects are mild and uncommon: headache, heartburn, insomnia, dizziness, and skin rash. A 2021 retrospective cohort study raised a question about long-term Alpha-GPC use and stroke risk in older adults, though the study design (observational, not randomized) limits causal conclusions.
Drug interactions: Alpha-GPC may enhance the effects of acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) used for Alzheimer's disease. Individuals taking anticholinergic medications should be aware that Alpha-GPC works in the opposite direction. Consult a physician before combining with any medication that affects cholinergic signaling.